American Renal Associates Holdings, Inc (ARA) Upgraded by Zacks Investment Research to “Buy”

Zacks Investment Research upgraded shares of American Renal Associates Holdings, Inc (NYSE:ARA) from a hold rating to a buy rating in a research report report published on Tuesday, July 11th. Zacks Investment Research currently has $20.00 price objective on the stock.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

Separately, Wells Fargo & Company raised American Renal Associates Holdings from a market perform rating to an outperform rating in a report on Thursday, May 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $25.50.

American Renal Associates Holdings (NYSE:ARA) traded up 2.70% during mid-day trading on Tuesday, hitting $14.44. The stock had a trading volume of 305,057 shares. The stock’s market cap is $451.76 million. The firm has a 50-day moving average of $17.50 and a 200-day moving average of $18.15. American Renal Associates Holdings has a 52-week low of $13.74 and a 52-week high of $25.42.

American Renal Associates Holdings (NYSE:ARA) last posted its earnings results on Tuesday, August 8th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.12 by $0.04. The firm had revenue of $185.99 million for the quarter, compared to analyst estimates of $188.23 million. American Renal Associates Holdings had a positive return on equity of 18.25% and a negative net margin of 1.54%. The company’s revenue for the quarter was up .2% compared to the same quarter last year. On average, analysts forecast that American Renal Associates Holdings will post $0.54 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/08/11/american-renal-associates-holdings-inc-ara-upgraded-to-buy-at-zacks-investment-research-updated-updated-updated.html.

A number of institutional investors have recently added to or reduced their stakes in ARA. Atria Investments LLC increased its position in American Renal Associates Holdings by 2.2% in the second quarter. Atria Investments LLC now owns 10,943 shares of the company’s stock valued at $203,000 after buying an additional 233 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in American Renal Associates Holdings by 0.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 39,132 shares of the company’s stock valued at $726,000 after buying an additional 285 shares in the last quarter. Rhumbline Advisers increased its position in American Renal Associates Holdings by 2.7% in the second quarter. Rhumbline Advisers now owns 13,383 shares of the company’s stock valued at $248,000 after buying an additional 354 shares in the last quarter. Alliancebernstein L.P. increased its position in American Renal Associates Holdings by 3.0% in the second quarter. Alliancebernstein L.P. now owns 13,900 shares of the company’s stock valued at $258,000 after buying an additional 400 shares in the last quarter. Finally, Teachers Advisors LLC increased its position in American Renal Associates Holdings by 8.8% in the second quarter. Teachers Advisors LLC now owns 17,910 shares of the company’s stock valued at $332,000 after buying an additional 1,444 shares in the last quarter. Institutional investors own 90.93% of the company’s stock.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates Holdings (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for American Renal Associates Holdings (NYSE:ARA)

What are top analysts saying about American Renal Associates Holdings Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for American Renal Associates Holdings Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit